KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Payables (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Payables for 9 consecutive years, with $15.6 million as the latest value for Q4 2025.

  • Quarterly Payables fell 43.02% to $15.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.6 million through Dec 2025, down 43.02% year-over-year, with the annual reading at $15.6 million for FY2025, 43.02% down from the prior year.
  • Payables hit $15.6 million in Q4 2025 for Bionano Genomics, down from $15.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $80.2 million in Q4 2023 to a low of $2.2 million in Q1 2021.
  • Historically, Payables has averaged $18.6 million across 5 years, with a median of $15.5 million in 2023.
  • Biggest five-year swings in Payables: soared 539.76% in 2023 and later plummeted 65.92% in 2024.
  • Year by year, Payables stood at $10.8 million in 2021, then grew by 16.39% to $12.5 million in 2022, then skyrocketed by 539.76% to $80.2 million in 2023, then tumbled by 65.92% to $27.3 million in 2024, then plummeted by 43.02% to $15.6 million in 2025.
  • Business Quant data shows Payables for BNGO at $15.6 million in Q4 2025, $15.8 million in Q3 2025, and $18.0 million in Q2 2025.